Stephen Su
The Heart Research Institute
14 Papers
165 Citations
Stephen Su is an academic researcher from The Heart Research Institute. The author has contributed to research in topics: Janus kinase & Riboside. The author has an hindex of 9, co-authored 14 publications.
Chat about Author
Papers
A CSF-1 receptor kinase inhibitor targets effector functions and inhibits pro-inflammatory cytokine production from murine macrophage populations
Katharine M. Irvine,Christopher J. Burns,Andrew F. Wilks,Stephen Su,David A. Hume,Matthew J. Sweet +5 more
TL;DR: In thioglycollate‐elicited peritoneal macrophages (TEPM), CYC10268 impaired LPS‐induced cytokine production and regulated expression of known CSF‐1 target genes, supporting the conclusion that TEPM are CSF•1 autocrine and that CSf‐1 plays a central role in macrophage effector functions during inflammation.
92
Colony-stimulating factor-1 (CSF-1) delivers a proatherogenic signal to human macrophages
Katharine M. Irvine,Melanie R. Andrews,Manuel A. Fernandez-Rojo,Kate Schroder,Christopher J. Burns,Stephen Su,Andrew F. Wilks,Robert G. Parton,David A. Hume,Matthew J. Sweet +9 more
TL;DR: The data demonstrate that CSF‐1 represents a further link between inflammation and cardiovascular disease and suggest two distinct mechanisms by which CSF, which is known to be present in atherosclerotic lesions, may contribute to plaque progression.
89
Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs).
Christopher J. Burns,David Gerard Bourke,Laura Andrau,Xianyong Bu,Susan A. Charman,Andrew Craig Donohue,Emmanuelle Fantino,Michelle Farrugia,John Thomas Feutrill,Max Joffe,R Marcel Kling,Margarita Kurek,Tracy L. Nero,Thao Kim Nu Nguyen,James T. Palmer,Ian D Phillips,David M. Shackleford,Harrison Sikanyika,Michelle Leanne Styles,Stephen Su,Herbert R. Treutlein,Jun Zeng,Andrew F. Wilks +22 more
TL;DR: Developing this initial series of phenylaminopyrimidines led to the potent JAK2/JAK1 inhibitor CYT387 (N-(cyanomethyl)-4-[2-[[4-morpholinyl]amino]-4-pyrimidinyl]-benzamide).
75
C8c-C15 monoseco-analogues of the phenanthroquinolizidine alkaloids julandine and cryptopleurine exhibiting potent anti-angiogenic properties.
Martin G. Banwell,Anna Bezos,Christopher J. Burns,Irma Kruszelnicki,Christopher R. Parish,Stephen Su,Magne O. Sydnes +6 more
TL;DR: These analogues of the phenanthroquinolizidine alkaloid julandine and four of congener cryptopleurine show dramatically reduced cytotoxicity compared with the parent system 2 but they are, nevertheless, potent anti-angiogenic agents.
52
CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo
Christopher J. Burns,Emmanuelle Fantino,Ian D Phillips,Stephen Su,Michael Francis Harte,P. Bukczynska,Mark Frazzetto,Max Joffe,Irma Kruszelnicki,Bing Wang,Yue Wang,Neil Wilson,Rodney J. Dilley,Soo San Wan,Susan A. Charman,David M. Shackleford,Rosa Fida,Cathy Malcontenti-Wilson,Andrew F. Wilks +18 more
TL;DR: CYT997 is a wholly synthetic compound that possesses highly potent cytotoxic activity in vitro through inhibition of microtubule polymerization and has considerable potential as a novel anticancer agent.
32